Metabolic Bulk Volume is an independent prognostic factor and facilitates identifying high risk cases for DLBCL patients treated with the R-CHOP

Key Points

• High risk DLBCL patients can be better identified using metabolic bulk volume as a prognostic factor, improving outcomes.
• Increased tumor dissemination and total tumor burden combined with metabolic bulk volume significantly aids in risk stratification.
• Assessment utilized existing parameters to evaluate the prognostic capabilities of metabolic bulk volume in DLBCL cases.
• These findings suggest important implications for treatment planning and patient management in DLBCL, warranting broader application.